- Home
- ENSC vs DWTX Comparison
ENSC vs DWTX Comparison
Compare ENSC & DWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- DWTX
- Stock Information
- Founded
- ENSC 2003
- DWTX 2012
- Country
- ENSC United States
- DWTX United States
- Employees
- ENSC N/A
- DWTX N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- DWTX
- Sector
- ENSC Health Care
- DWTX
- Exchange
- ENSC Nasdaq
- DWTX NYSE
- Market Cap
- ENSC 5.5M
- DWTX 5.9M
- IPO Year
- ENSC N/A
- DWTX N/A
- Fundamental
- Price
- ENSC $2.29
- DWTX $4.18
- Analyst Decision
- ENSC
- DWTX
- Analyst Count
- ENSC 0
- DWTX 0
- Target Price
- ENSC N/A
- DWTX N/A
- AVG Volume (30 Days)
- ENSC 31.4K
- DWTX 3.1M
- Earning Date
- ENSC 05-12-2025
- DWTX 03-31-2025
- Dividend Yield
- ENSC N/A
- DWTX N/A
- EPS Growth
- ENSC N/A
- DWTX N/A
- EPS
- ENSC N/A
- DWTX N/A
- Revenue
- ENSC $5,210,031.00
- DWTX N/A
- Revenue This Year
- ENSC N/A
- DWTX N/A
- Revenue Next Year
- ENSC N/A
- DWTX N/A
- P/E Ratio
- ENSC N/A
- DWTX N/A
- Revenue Growth
- ENSC 133.58
- DWTX N/A
- 52 Week Low
- ENSC $2.12
- DWTX $1.62
- 52 Week High
- ENSC $14.67
- DWTX $29.28
- Technical
- Relative Strength Index (RSI)
- ENSC 20.64
- DWTX N/A
- Support Level
- ENSC $2.19
- DWTX N/A
- Resistance Level
- ENSC $2.70
- DWTX N/A
- Average True Range (ATR)
- ENSC 0.32
- DWTX 0.00
- MACD
- ENSC -0.06
- DWTX 0.00
- Stochastic Oscillator
- ENSC 5.69
- DWTX 0.00
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.